Thomas N Bohjalian

Director Thomas N Bohjalian purchases 75,000 shares of SMRT at $1.11; stock now $1.09, down 50.4% from 52-week high and 33.9% in 90 days.

Director Thomas N Bohjalian purchased 75,000 shares at $1.11 on 2026-06-10, increasing his stake by 11.6% to 721,062 shares post-transaction. The timing follows a sharp 90-day decline of -33.9% in SMRT's price. His prior trading activity at SMRT shows mixed results: of his 5 preceding buys at this ticker, only 1 was followed by positive 90-day returns (a 20% win rate). The company is unprofitable (net income of $-4.4M in latest quarter) with declining fundamentals (annual revenue growth of -12.9%). The director's cross-ticker track record shows 17 prior buys with an average 90-day win rate of 46.67%, suggesting modest predictive value at other securities. This purchase, made against a backdrop of continued stock weakness and uneven personal timing success at this ticker, merits investor attention as a data point but does not unambiguously signal conviction given the company's financial stress and the insider's historical outcomes at SMRT.

Director Bohjalian buys 150,000 shares of SMRT at $1.74; holdings rise to 500,000 (+42.9%)

Bohjalian purchased 150,000 shares at $1.74 on 2026-03-12, a substantial 42.9% increase to his post-transaction holdings of 500,000 shares. The stock now trades at $1.65, down 22.2% from its 52-week high of $2.12, suggesting the transaction occurred at an elevated price relative to current market levels. His prior trades at SmartRent show mixed timing: 2 of 5 buys resulted in positive 90-day returns, while 3 resulted in declines, indicating inconsistent predictive success at this specific ticker. Against this backdrop, the company faces structural headwinds—annual revenue contracted 12.9% year-over-year to $36.2M in the latest quarter, and the firm posted a net loss of $6.3M, underscoring persistent unprofitability.

Director Bohjalian buys 10,000 HR shares at $18.09; holdings rise to 85.5K; stock currently $18.39 despite unprofitable full-year financials.

Thomas N Bohjalian, a director at Healthcare Realty Trust Inc, purchased 10,000 shares at $18.09 on 2026-03-06, increasing his stake to 85.5K shares (+13.2% vs pre-transaction holdings). The purchase occurs near the top of the 52-week trading range ($14.18–$18.88), with the stock 2.6% below its 52-week high. However, the company's fundamentals are concerning: it reported a net loss of $-57.7M on revenue of $297.8M in the latest quarter, with annual revenue declining 6.9% year-over-year and a markedly elevated P/E of 153.25 reflecting unprofitable operations. Among his prior five purchases at this ticker, his timing has been mixed—two of the five prior buys showed positive 90-day returns, while three showed losses ranging from -1.9% to -6.6%. The current buy price aligns with recent 30-day momentum (+11.0%) but arrives at a valuation inflection point given the company's negative earnings trajectory and weak annual growth, warranting examination of whether this purchase reflects confidence in a turnaround or routine portfolio activity.

Director Bohjalian bought 50,000 SMRT shares at $1.68; post-transaction holding 350,000 shares (+16.7%)

Bohjalian Thomas N purchased 50,000 shares at $1.68 on 2025-12-02, increasing his SMRT holdings from 300,000 to 350,000 shares (+16.7%). SmartRent is unprofitable with net income of $-6,270,000.00 against quarterly revenue of $36,202,000.00, and is experiencing revenue contraction (-26.2% annual growth). Of Bohjalian's 4 prior trades at SMRT, 2 proved well-timed at the 90-day mark, but the current purchase occurs at $1.68 against a 52-week high of $1.96 and a current price of $1.71 (+23.0% in the past 30 days). His cross-ticker track record shows an average 90-day return of +1.6% with a 45.45% win rate, indicating modest timing accuracy across his broader trading activity.

Director Bohjalian buys 125,000 SMRT shares in 2 transactions for $187,250.00; cluster pattern with 2 other insiders buying within 14 days

Thomas N Bohjalian, a Director at SmartRent, executed 2 separate purchases totaling 125,000 shares (125.0K shares) for $187,250.00 on August 18–19, 2025, at a blended average price of $1.50, bringing his holdings from 175,000 shares to 300,000 shares—a +71.4% increase in his stake. The stock was trading at the blended transaction price of $1.50 at filing, within its 52-week range of $0.72–$1.96 and currently -23.5% from the 52-week high, having gained 55.3% over the past 30 days and 80.3% over the past 90 days. The company reported revenue of $38.3M in the latest quarter with a net loss of $-10.9M, annual revenue contraction of -26.2%, and negative full-year net income—indicating ongoing unprofitability. This transaction is part of a broader cluster pattern in which 2 other insiders also bought within the past 14 days, suggesting possible coordinated confidence. Bohjalian's cross-ticker trading history shows 12 prior buys with a 42.86% win rate at the 90-day mark and an average 90d return of +0.4%, with his 2 most recent purchases at SMRT (on August 11–12) outcomes still unmeasurable.

Director Bohjalian buys 10,000 HR shares at $16.46; holdings increase 15.3% to 75,520 shares

Bohjalian, a director of Healthcare Realty Trust, purchased 10,000 shares at $16.46 on 2025-08-13, expanding his position by 15.3% from 65,520 to 75,520 shares. The stock has since moved to $16.67 and has appreciated 4.1% over the past 30 days and 12.7% over 90 days. His prior buy at HR on 2025-05-13 delivered +1.4% in 30 days and +13.7% in 90 days, but his other four purchases at this ticker (2024-11-22 and 2024-09-04) generated negative 30-day and 90-day returns. The company remains unprofitable with full-year net income of $-157.9M and annual revenue has contracted 5.6% year-over-year, which provides material headwinds despite the director's accumulation.

Director Thomas Bohjalian purchases 175,000 SMRT shares at $1.26–$1.37 for $223,250 total.

Bohjalian, a director, executed two separate purchases totaling 175,000 shares for $223,250.00 across 2025-08-11 and 2025-08-12, establishing an initial stake at an average of $1.28 per share. The stock has risen 30-day (+38.8%) and 90-day (+72.1%) but remains -30.6% from its 52-week high of $1.96. The company faces material headwinds: revenue contracted -26.2% year-over-year, it posted a net loss of $-10.9M last quarter, and was unprofitable over the full prior fiscal year. Bohjalian's cross-ticker track record across 9 prior buys shows a 42.86% 90-day win rate with average 90-day returns of +0.4%, indicating modest historical success in timing purchases. The scale of this new position—175,000 shares from zero prior holdings—combined with the company's revenue decline and ongoing losses, merits investor attention to the motivation behind and competitive position context for this entry.

Director Bohjalian bought 2,500 shares of HR at $14.71, holding 56,502 shares post-transaction. Stock down 22.5% from 52-week high; unprofitable company.

Director Thomas N Bohjalian purchased 2,500 shares at $14.71, increasing his holdings by 4.6% to 56,502 shares. The buy occurs against a backdrop of deteriorating fundamentals and price weakness: the company posted negative net income of $-44,873,000.00 over its most recent full fiscal year, annual revenue declined 5.6%, and the stock is -22.5% from its 52-week high and -8.1% over 30 days. His prior 5 purchases at HR delivered mixed results—only 1 of 5 were well-timed at the 90-day horizon, with the most recent batch of three purchases on 2024-11-22 all showing losses at both 30-day and 90-day marks (-2.6% to -4.9% at 90 days). The modest transaction size ($36,775.00) and continuation of a buying pattern despite recent poor outcomes and fundamental headwinds presents a data point for ongoing observation of insider positioning in an unprofitable REIT under price pressure.

Director Bohjalian buys 7,750 shares at $17.34–$17.75 for $134,795; holdings rise to 50,002 shares (+18.3%).

Director Thomas N. Bohjalian executed 2 separate purchases totaling 7,750 shares for $134,795.00 on 2024-11-22, increasing his post-transaction holdings to 50,002 shares (a net increase of 18.3% versus his pre-transaction position of 42,252 shares). The blended average price of $17.39 is marginally above the current price of $17.30 and well below the 52-week high of $18.78 (current price is -7.9% from that high). Bohjalian's prior trades at Healthcare Realty Trust show mixed outcomes: his last two measurable 90-day periods yielded -0.1% and +2.2% respectively, with only 1 of 2 prior 90-day buys being well-timed. The company carries fundamental headwinds—latest quarter net income of $-93,023,000.00 (negative), though annual revenue growth of +44.1% shows topline expansion.

Director Bohjalian Thomas N purchased 4,000 shares of HR at $17.20 on 2024-11-22, increasing holdings to 54,002 shares.

Bohjalian purchased 4,000 shares at $17.20, expanding his position by 8.0% to 54,002 shares. The stock has declined 5.2% over the past 30 days and 7.9% from its 52-week high of $18.78, trading at $17.30 currently. At Healthcare Realty Trust, Bohjalian's same-ticker history shows mixed results: his buy on 2024-08-12 achieved 90-day returns of +2.2%, while his buy on 2024-08-20 achieved 90-day returns of -0.1%, placing his timing success at 50% on measurable outcomes. The company is unprofitable (net income of $-93.0M most recently) despite strong revenue growth of 44.1% year-over-year, signaling operational challenges that warrant monitoring given the scale of losses against a $6.1B market cap.